Mitsubishi Tanabe Pharma America to Present Parkinson's Research at 10th EAN Congress

Mitsubishi Tanabe Pharma America, Inc. (MTPA) has announced plans to present research findings on the investigational drug ND0612 at the 10th Congress of the European Academy of Neurology (EAN) in Helsinki, Finland. The event will take place from June 29 to July 2, 2024. ND0612 is being studied as a potential treatment for Parkinson's disease (PD).

"Being at EAN allows us to share our research and connect with the scientific community," said Gustavo A. Suarez Zambrano, M.D., Vice President of Medical Affairs at MTPA. "These presentations underscore our commitment to advancing the understanding of ND0612 and addressing the unmet needs of Parkinson's patients."

The presentations will cover various aspects of ND0612, including results from a Phase 3 trial and a secondary analysis from a Phase 2 study. One presentation will focus on subgroup analyses from the BouNDless trial (NCT04006210), a pivotal Phase 3 study that evaluated the efficacy, safety, and tolerability of ND0612 in patients with Parkinson's experiencing motor fluctuations. Another presentation will discuss the onset of efficacy of ND0612 based on patient and clinical global ratings from a Phase 2 study (NCT02577523). Additionally, an analysis that characterizes infusion site reactions in patients who underwent a 24-hour subcutaneous infusion of ND0612 will be presented.

The specific presentation details are as follows:

1. Subgroup Analyses of a Phase 3, Randomized Study of Levodopa/Carbidopa Infusion (ND0612) for Parkinson's Patients - This session will be conducted by Nelson Lopes, M.D. of NeuroDerm. It is scheduled for June 29, from 2:10 p.m. to 2:15 p.m. CEST, under the ePresentation session titled "Movement Disorders 1" (EPR-082).

2. Onset of Efficacy with Levodopa/Carbidopa Infusion (ND0612) for Parkinson's Patients - Also led by Nelson Lopes, M.D. of NeuroDerm, this presentation will take place on June 29, from 2:15 p.m. to 2:20 p.m. CEST, as part of the "Movement Disorders 1" session (EPR-083).

3. Characterization of Infusion Site Reactions With 24-hour Subcutaneous Infusion of ND0612 - This final presentation by Nelson Lopes, M.D., is scheduled for June 29, from 2:20 p.m. to 2:25 p.m. CEST, also within the "Movement Disorders 1" session (EPR-084).

ND0612 is a continuous subcutaneous infusion of liquid levodopa/carbidopa (LD/CD) designed to manage motor fluctuations in Parkinson's patients. The development of this investigational therapy is led by NeuroDerm, Ltd., an entity fully owned by Mitsubishi Tanabe Pharma Corporation (MTPC).

Mitsubishi Tanabe Pharma America, Inc. (MTPA), headquartered in Jersey City, N.J., focuses on developing and commercializing pharmaceutical products in North America. It was established by MTPC, which is a part of Mitsubishi Chemical Group and has a long history dating back to its founding in 1678. MTPC is headquarted in Doshomachi, Osaka, the heart of Japan's pharmaceutical industry.

MTPC is dedicated to creating solutions for various diseases, including those affecting the central nervous system, immune system, diabetes, kidney, and cancer. It emphasizes precision medicine and aims to provide highly satisfactory treatment options while also developing solutions that address broader patient needs, from disease prevention to prognosis.

NeuroDerm, Ltd., based in Israel, is a subsidiary of MTPC and focuses on developing innovative drug-device combination therapies for central nervous system (CNS) disorders. The company strives to improve the quality of life for patients and their families through these advanced treatments.